Drug Detail

Drug Name Pembrolizumab
Trade Name Keytruda
Synonyms MK-3475
Drug Descriptions

Keytruda (pembrolizumab) is an antibody that binds to and inhibits PD-1, resulting in activation of T-cell mediated immune response against tumor cells (PMID: 25977344). Keytruda (pembrolizumab) is approved for use in patients with melanoma, head and neck squamous cell carcinoma, classical Hodgkin Lymphoma, primary mediastinal large B-cell lymphoma, urothelial carcinoma, hepatocellular carcinoma, Merkel cell carcinoma, MSI-H or dMMR solid tumors, PD-L1 expressing NSCLC, gastric cancer, GEJ adenocarcinoma, and cervical cancer, in combination with pemetrexed and platinum in non-squamous NSCLC with no EGFR or ALK mutations, and in combination with carboplatin and paclitaxel/nab-paclitaxel in squamous NSCLC (FDA.gov).

DrugClasses Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Therapy Name Therapy Description
Niraparib + Pembrolizumab
Pembrolizumab + Vorinostat
MK-4830 + Pembrolizumab
Carboplatin + Pembrolizumab + Olaparib
Binimetinib + Pembrolizumab
LYC-55716 + Pembrolizumab
Azacitidine + Pembrolizumab
Entinostat + Pembrolizumab
INCB024360 + Pembrolizumab + Carboplatin + Paclitaxel
Pembrolizumab + Paricalcitol + Gemcitabine + nab-paclitaxel
FLX475 + Pembrolizumab FLX475 is a CCR4 antagonist, which may decrease migration of regulatory T-cells into the tumor microenvironment (PMID: 30344896).
Doxil + Pembrolizumab
FT500 + Pembrolizumab FT500 is a Natural Killer cell product clonally derived from iPSC cells, which has potential cytotoxic effects against tumors (Cancer Res 2018;78 (13 Suppl):Abstract nr 3576).
Pembrolizumab + Anetumab ravtansine
Defactinib + Pembrolizumab
MGAH22 + Pembrolizumab
Nivolumab + Pembrolizumab
Pembrolizumab + Temozolomide + Vorinostat
Pembrolizumab + Tisotumab Vedotin
Pembrolizumab + Vemurafenib
Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed
Paclitaxel + Pembrolizumab + Pertuzumab + Trastuzumab
MK-1308 + Pembrolizumab
Epacadostat + Pembrolizumab
ALKS 4230 + Pembrolizumab ALKS 4230 is a fusion protein of IL2 and IL2RA, which activates effector lymphocytes upon binding to intermediate affinity IL2 receptors to enhance cell death of tumor cells (AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 4088).
Oraxol + Pembrolizumab
Bevacizumab + Capecitabine + Pembrolizumab
Pembrolizumab + PVX-410
Pembrolizumab + TRK-950
Pembrolizumab + Vicriviroc Vicriviroc (MK-7690) is a CCR5 antagonist, which potentially decreases tumor cell invasiveness and metastasis (PMID: 22637726).
IL-12 gene + Pembrolizumab
Dasatinib + Pembrolizumab
Cyclophosphamide + Pembrolizumab
INCB024360 + Pembrolizumab + Carboplatin + Pemetrexed
Bevacizumab + Carboplatin + Pembrolizumab + Olaparib
MK-4280 + Pembrolizumab
Guadecitabine + Pembrolizumab
Pembrolizumab + Cabozantinib
MK-1454 + Pembrolizumab
Pegzilarginase + Pembrolizumab
Pembrolizumab + Ad-MAGEA3 + MG1-MAGEA3
Apatinib + Pembrolizumab
Docetaxel + Doxorubicin + Pembrolizumab
Carboplatin + Pembrolizumab
Imiquimod + Pembrolizumab
GLA-SE + Pembrolizumab
Pembrolizumab + Ra 223
NKTR-214 + Pembrolizumab
Pembrolizumab + Decitabine
Nilotinib + Pembrolizumab
Fulvestrant + Pembrolizumab
INCB024360 + Pembrolizumab + Cyclophosphamide
Epacadostat + Pembrolizumab + Tavokinogene telseplasmid Tavokinogene telseplasmid is a plasmid encoding IL-12, which can delivered intratumorally by electroporation, potentially resulting in increased anti-tumor immune response (PMID: 29064334).
Celecoxib + Interferon alpha-2b + Pembrolizumab + Rintatolimod Rintatolimod is a dsRNA polymer and a restricted Toll-Like Receptor 3 agonist that lacks activation of other primary cellular inducers of innate immunity, and has broad antiviral and immunomodulatory properties (PMID: 27045557).
Olaparib + Paclitaxel + Pembrolizumab
DNX-2401 + Pembrolizumab
CRS-207 + INCB024360 + Pembrolizumab
Pembrolizumab + Sunitinib
Pembrolizumab + DPX-Survivac + Cyclophosphamide
Cyclophosphamide + GVAX pancreatic cancer vaccine + LY3022855 + Pembrolizumab
Abemaciclib + Pembrolizumab
Navarixin + Pembrolizumab
Pembrolizumab + Sorafenib
Pembrolizumab + X4P-001
Nivolumab + Pembrolizumab + Trigriluzole
Mirvetuximab Soravtansine + Pembrolizumab Mirvetuximab Soravtansine (IMGN853) is an antibody-drug conjugate comprised of an antibody directed against Folr1 linked to the tubulin polymerization-inhibiting drug DM4, leading to cell death in Folr1-expressing tumors (PMID: 26136852, PMID: 25904506).
Pembrolizumab Keytruda (pembrolizumab) is an antibody that binds to and inhibits PD-1, resulting in activation of T-cell mediated immune response against tumor cells (PMID: 25977344). Keytruda (pembrolizumab) is approved for use in patients with melanoma, head and neck squamous cell carcinoma, classical Hodgkin Lymphoma, primary mediastinal large B-cell lymphoma, urothelial carcinoma, hepatocellular carcinoma, Merkel cell carcinoma, MSI-H or dMMR solid tumors, PD-L1 expressing NSCLC, gastric cancer, GEJ adenocarcinoma, and cervical cancer, in combination with pemetrexed and platinum in non-squamous NSCLC with no EGFR or ALK mutations, and in combination with carboplatin and paclitaxel/nab-paclitaxel in squamous NSCLC (FDA.gov).
Eribulin + Pembrolizumab
Lenvatinib + Pembrolizumab
Bevacizumab + Olaparib + Paclitaxel + Pembrolizumab
Paclitaxel + Pembrolizumab
Pembrolizumab + talimogene laherparepvec
Metformin + Pembrolizumab
Enadenotucirev + Pembrolizumab
L-NMMA + Pembrolizumab
CRS-207 + Cyclophosphamide + GVAX panc vaccine + INCB024360 + Pembrolizumab
Epacadostat + INCAGN01876 + Pembrolizumab
EDP1503 + Pembrolizumab
coxsackievirus A21 + Pembrolizumab
PEGPH20 + Pembrolizumab
LMB-100 + Pembrolizumab
Guadecitabine + Mocetinostat + Pembrolizumab
Demcizumab + Pembrolizumab
Pembrolizumab + Dabrafenib
CART-EGFRvIII + Pembrolizumab CART-EGFRvIII comprises autologous T-cells engineered with a lentiviral vector to express a chimeric antigen receptor that targets EGFRvIII-expressing tumor cells, which may have anti-tumor activity (PMID: 25696001, PMID: 25696001).
Pembrolizumab + RP6530
Dexamethasone + Pembrolizumab + Pomalidomide
Doxorubicin + Gemcitabine + Pembrolizumab + Vinorelbine Adriamycin (doxorubicin) is an anthracycline chemotherapeutic, in a non-liposomal formulation, which intercalates into DNA and inhibits topoisomerase II (PMID: 24367159). Doxorubicin is FDA approved for multiple cancer types (FDA.gov).
Capecitabine + Pembrolizumab
Enzalutamide + Pembrolizumab
MK-7162 + Pembrolizumab
Pembrolizumab + Yttrium-90
Bevacizumab + Carboplatin + Pembrolizumab
Pazopanib + Pembrolizumab
177Lu-PSMA-617 + Pembrolizumab 177Lu-PSMA-617 is a radioconjugate comprising a PSMA inhibitor radiolabeled with Lu177, which targets PSMA expressing cells, potentially resulting in decreased tumor growth (PMID: 25883127, PMID: 26795286).
Aldesleukin + Cyclophosphamide + Fludarabine + Pembrolizumab
Aldesleukin + Cyclophosphamide + Fludarabine + Mesna + Pembrolizumab
GSK3359609 + Pembrolizumab
peginterferon alfa-2b + Pembrolizumab
ADXS-503 + Pembrolizumab ADXS-503 is an attenuated Listeria monocytogenes expressing tumor specific hotspot antigens, including KRAS G12D, which may induce cytotoxic immune response against tumor cells (Cancer Res 2018; 78 (13 Suppl):Abstract nr LB-149).
Pemigatinib + Pembrolizumab
Cisplatin + Fluorouracil + Pembrolizumab + Trastuzumab
Pembrolizumab + Dabrafenib + Trametinib
Pembrolizumab + Pexidartinib
Cisplatin + Gemcitabine + Pembrolizumab
Pembrolizumab + Utomilumab
Cyclophosphamide + Interferon alpha-2b + Pembrolizumab + SV-BR-1-GM
nab-paclitaxel + Pembrolizumab
Pembrolizumab + Tretinoin
Fludarabine + Ibrutinib + Pembrolizumab
Pembrolizumab + Umbralisib
Bevacizumab + Paclitaxel + Pembrolizumab
Pembrolizumab + Ruxolitinib
Pembrolizumab + Sargramostim
Grapiprant + Pembrolizumab
Carboplatin + Pembrolizumab + Pemetrexed + Rucaparib
GSK2857916 + Pembrolizumab GSK2857916 is an antibody-drug conjugate comprising an antibody targeting BCMA linked to monomethyl auristatin F, which delivers the anti-microtubule agent to BCMA-expressing tumor cells, potentially resulting in increased tumor cell death and decreased tumor growth (PMID: 30442502, PMID: 24569262).
Pembrolizumab + Etoposide + Carboplatin + Ifosfamide
BDB0001 + Pembrolizumab
Mifepristone + Pembrolizumab
Pembrolizumab + Topotecan
Atezolizumab + Enfortumab vedotin + Pembrolizumab
IMO-2125 + Pembrolizumab
BKT140 + Pembrolizumab
MK-8353 + Pembrolizumab
Pembrolizumab + SEA-CD40
NY-ESO-1-c259T + Pembrolizumab
Pembrolizumab + Trametinib
Pembrolizumab + Tavokinogene telseplasmid
Defactinib + Gemcitabine + Pembrolizumab
Irinotecan + Pembrolizumab
Capecitabine + Oxaliplatin + Pembrolizumab + Trastuzumab
Azacitidine + INCB024360 + Pembrolizumab
Cisplatin + Etoposide + Pembrolizumab
Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab
mRNA-4157 + Pembrolizumab
Pembrolizumab + Preladenant
Cyclophosphamide + ONCOS-102 + Pembrolizumab
Azacitidine + Pembrolizumab + Romidepsin
Pembrolizumab + interferon gamma
Pembrolizumab + XL888
Oxaliplatin + Pembrolizumab + Trastuzumab + TS-1
GRN-1201 + Pembrolizumab
MVAp53 + Pembrolizumab
Pembrolizumab + Vorolanib
ABVD (Bleomycin + Dacarbazine + Doxorubicin + Vinblastine) + Pembrolizumab
Cisplatin + Pembrolizumab + Rintatolimod Rintatolimod is a synthetic dsRNA molecule that activates TLR3 and other interferon-induced proteins, which may have anticancer effects (PMID: 27045557, PMID: 19200817).
Pembrolizumab + Trastuzumab
Carboplatin + Cisplatin + Etoposide + Pembrolizumab
MK-1248 + Pembrolizumab
Carboplatin + Paclitaxel + Pembrolizumab + Olaparib
Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab
Daratumumab + Pembrolizumab
Imprime PGG + Pembrolizumab
CM-24 + Pembrolizumab
Pembrolizumab + Radiotherapy
Lanreotide Depot + Pembrolizumab
Doxorubicin + Pembrolizumab
Radiotherapy + Temozolomide + Pembrolizumab
Romidepsin + Pembrolizumab
Pembrolizumab + rAd.CD40L
Dacarbazine + Doxorubicin + Pembrolizumab +Vinblastine
Epirubicin + Pembrolizumab
Indoximod + Pembrolizumab
Pembrolizumab + Rituximab
AST-008 + Pembrolizumab Limited information is currently available on AST-008 (Jan, 2019).
Pembrolizumab + trastuzumab emtansine
Blinatumomab + Pembrolizumab
MGA271 + Pembrolizumab
Pembrolizumab + RO6874281 RO6874281 is a fusion protein consists of a human anti-fibroblast activation protein-alpha (FAP) antibody and an engineered interleukin-2, which may stimulate local immune response against FAP-positive tumor cells (NCI Drug Dictionary).
Pembrolizumab + Trebananib
Afatinib + Pembrolizumab
Carboplatin + Paclitaxel + Pembrolizumab
Clostridium novyi-NT spores + Doxycycline + Pembrolizumab
Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab + Olaparib
BGB-324 + Pembrolizumab
Aldesleukin + Pembrolizumab
ARRY-382 + Pembrolizumab
Olaratumab + Pembrolizumab
Paclitaxel + Pembrolizumab + Trastuzumab
Cyclophosphamide + Epirubicin + Pembrolizumab
Capecitabine + Oxaliplatin + Pembrolizumab
sEphB4-HSA + Pembrolizumab
Aldesleukin + Cyclophosphamide + Pembrolizumab
Bavituximab + Pembrolizumab
COPDAC-28 + Pembrolizumab
Pembrolizumab + Cetuximab
HER2 BATs + Pembrolizumab
Cyclophosphamide + GVAX colorectal cancer vaccine + Pembrolizumab
Carboplatin + nab-paclitaxel + Pembrolizumab
Pembrolizumab + XmAb22841 Limited information is currently available on XmAb22841, a putative CTLA-4 and LAG-3 bispecific antibody (Feb, 2019).
Binimetinib + FOLFIRI + Pembrolizumab
Pembrolizumab + Tamoxifen + vorinostat
Cyclophosphamide + Epirubicin + Paclitaxel + Pembrolizumab
Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab
Olaparib + Pembrolizumab
Pembrolizumab + Tabelecleucel Tabelecleucel (ATA129) is a preparation of donor-derived EBV-specific cytotoxic T-cells, which may decrease growth of EBV-positive tumors (NCI Drug Dictionary).
Canakinumab + Pembrolizumab
MRx0518 + Pembrolizumab
ASP8374 + Pembrolizumab
MK-2118 + Pembrolizumab
CRS-207 + Pembrolizumab
Bevacizumab + Cisplatin + Paclitaxel + Pembrolizumab
lenalidomide + Pembrolizumab
Aldesleukin + Pembrolizumab + Radiotherapy
Idelalisib + Pembrolizumab
Pembrolizumab + SGN-LIV1A
DPX-Survivac + Pembrolizumab DPX-Survivac is a liposome-encapsulated cancer vaccine that contains Survivin epitopes, which may induce an immune response against Survivin-expressing tumor cells (NCI Drug Dictionary).
BCG solution + Pembrolizumab
Cyclophosphamide + Doxorubicin + Pembrolizumab
Cyclophosphamide + Doxorubicin + Paclitaxel + Pembrolizumab Keytruda (pembrolizumab) is an antibody that binds to and inhibits PD-1, resulting in activation of T-cell mediated immune response against tumor cells (PMID: 25977344). Keytruda (pembrolizumab) is approved for use in patients with melanoma, head and neck squamous cell carcinoma, classical Hodgkin Lymphoma, primary mediastinal large B-cell lymphoma, hepatocellular carcinoma, Merkel cell carcinoma, MSI-H or dMMR solid tumors, PD-L1 expressing NSCLC, gastric cancer, GEJ adenocarcinoma, urothelial carcinoma, and cervical cancer, in combination with pemetrexed and platinum in non-squamous NSCLC with no EGFR or ALK mutations, and in combination with carboplatin and paclitaxel/nab-paclitaxel in squamous NSCLC (FDA.gov).
GSK3145095 + Pembrolizumab GSK3145095, a small molecule RIPK-1 inhibitor with potential antineoplastic and immunomodulatory activities that may reduce CXCL1-driven recruitment and migration of immunosuppressive myeloid-derived suppressor cells, and allows Natural Killer and Cytotoxic T Lymphocytes to eliminate cancer cells. (NCI Drug Dictionary).
Letrozole + Palbociclib + Pembrolizumab
B-701 + Pembrolizumab
Dexamethasone + Docetaxel + Pembrolizumab + Prednisone
Pembrolizumab + Ublituximab + Umbralisib
Pembrolizumab + Reolysin Reolysin (pelareorep) is a reovirus, which specifically infects and replicates in RAS-activated cells to induce apoptosis, and may also induce anti-tumor immune response (PMID: 29799479).
Carboplatin + Pembrolizumab + Pemetrexed
FOLFIRI + Pembrolizumab
Bevacizumab + Pembrolizumab
Capecitabine + Epirubicin + Oxaliplatin + Pembrolizumab
Pembrolizumab + QbG10
Bevacizumab + Binimetinib + Pembrolizumab
Pembrolizumab + RO7198457 RO7198457 is a personalized mRNA based cancer vaccine that stimulates T-cell mediated immune response against tumor cells (NCI Drug Dictionary).
CDX-301 + Pembrolizumab + Poly ICLC
Birinapant + Pembrolizumab
MK-7684 + Pembrolizumab
LN-144 + Pembrolizumab LN-144 (autologous tumor infiltrating lymphocytes) is a preparation of tumor infiltrating lymphocytes isolated and expanded from patient tumor tissue, which may demonstrate enhanced anti-tumor immune activity when re-introduced into patients (Journal of Clinical Oncology 35, no. 15_suppl (May 20 2017) 3045-3045).
Pembrolizumab + poly ICLC
Docetaxel + Pembrolizumab
Pembrolizumab + Regorafenib
Carboplatin + Etoposide + Pembrolizumab
Ad-CCL21-DC + Pembrolizumab Ad-CCL21-DC vaccine is a cancer vaccine comprising dendritic cells engineered to express CCL21, which may induce an immune response against tumor cells (PMID: 28468947).
CDX-301 + Pembrolizumab Mobista (CDX-301) is a recombinant Flt3 ligand that binds to and activates the Flt3 receptor, leading to proliferation of immune precursor cells (PMID: 25915810).
Ipilimumab + Pembrolizumab
MK-5890 + Pembrolizumab
Aflibercept + Pembrolizumab
Pembrolizumab + SX-682
APX005M + Pembrolizumab
Capecitabine + Cisplatin + Pembrolizumab
Pembrolizumab + Propranolol
Bevacizumab + Cyclophosphamide + Pembrolizumab
Pembrolizumab + Temozolomide + Vitespen
GSK3745417 + Pembrolizumab Limited information is currently available on GSK3745417 (Mar, 2019).
Axitinib + Pembrolizumab
Epacadostat + INCB001158 + Pembrolizumab
LN-145 + Pembrolizumab LN145 comprises autologous tumor infiltrating lymphocytes that are isolated and expanded with IL-2, followed by infusion, potentially resulting in tumor cell death (NCI Drug Dictionary).
Imatinib + Pembrolizumab
GSK2636771 + Pembrolizumab
A-dmDT390-bisFv(UCHT1) + Pembrolizumab
Decitabine + Pembrolizumab + Pralatrexate
Pegilodecakin + Pembrolizumab
Abexinostat + Pembrolizumab
Cyclophosphamide + GVAX pancreatic cancer vaccine + Pembrolizumab
AFM13 + Pembrolizumab
Pembrolizumab + Gemcitabine
Gemcitabine + Nab-Paclitaxel + mFOLFOX-6
Cisplatin + Pembrolizumab + Pemetrexed
Galinpepimut-S + Pembrolizumab Galinpepimut-S is a WT1 vaccine comprised of four WT1 peptides, which may result in a CD4 and CD8 T cell immune response against WT1-expressing tumor cells (PMID: 28972039).
Mogamulizumab + Pembrolizumab Poteligeo (mogamulizumab-kpkc) is a monoclonal antibody that binds to and inhibits C-C chemokine receptor 4 (CCR4) signaling, which leads to inhibition of Tregs and enhancement of host antitumor immunity (PMID: 25496334). Poteligeo (mogamulizumab-kpkc) is FDA approved for adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome (FDA.gov).
Erlotinib + Pembrolizumab
ALT-803 + Pembrolizumab
Pembrolizumab + Ramucirumab
enobosarm + Pembrolizumab
Cisplatin + Fluorouracil + Pembrolizumab
Carboplatin + Docetaxel + Pegfilgrastim + Pembrolizumab
Dexamethasone + lenalidomide + Pembrolizumab
AVX901 + Pembrolizumab AVX901 is a virally based vaccine that infects cells and causes expression of a ERBB2 (HER2) ECD+TM protein that may activate the immune system to elicit a cytotoxic T-lymphocyte (CTL) response against ERBB2 (HER2)-expressing tumor cells (NCI Drug Dictionary).
Cisplatin + Pembrolizumab
Carboplatin + Gemcitabine + Pembrolizumab
Pembrolizumab + VSV-hIFNbeta-NIS
Carboplatin + NEO-PV-01 + poly ICLC + Pembrolizumab + Pemetrexed
Pembrolizumab + Temozolomide
CPI-006 + Pembrolizumab
Carboplatin + Docetaxel + Etoposide + Pembrolizumab
Denosumab + Pembrolizumab
Pembrolizumab + Paricalcitol
Pemetrexed + Pembrolizumab
Pembrolizumab + Tisagenlecleucel Kymriah (tisagenlecleucel) is a preparation of autologous T-lymphocytes engineered to express chimeric antigen receptors targeting CD19-positive cells, resulting in anti-tumor immune response (J Clin Oncol 35, 2017 (suppl; abstr 10523)). Kymriah (tisagenlecleucel) is FDA approved for pediatric and young adult patients with B-cell precursor acute lymphoblastic leukemia, and adult patient with elapsed or refractory large B-cell lymphoma (FDA.gov).
Cisplatin + Paclitaxel + Pembrolizumab
Dinaciclib + Pembrolizumab
Pembrolizumab + SD-101
Intuvax + Pembrolizumab
Pembrolizumab + Pralatrexate
Pembrolizumab + Vismodegib
Pembrolizumab + Interleukin-12
Gefitinib + Pembrolizumab
Pembrolizumab + Ibrutinib
AMG820 + Pembrolizumab
Itacitinib + Pembrolizumab
Capecitabine + Cisplatin + Pembrolizumab + Trastuzumab